Prognostic Implications of Codon-Specific <i>KRAS</i> Mutations in Localized and Advanced Stages of Pancreatic Cancer
These findings demonstrated that codon-specific <i>KRAS</i> mutations affect PDAC outcomes differently based on disease stage at diagnosis. As studies testing <i>KRAS</i> inhibitors continue to emerge and mature, the prognostic variability of individual <i>KRAS</i> mutations must be carefully considered to avoid confounding and ensure accurate evaluation of therapeutic efficacy in early-phase studies.
Authors
- Zahra Kabiri
- Peter J. Allen (ORCID: https://orcid.org/0000-0001-7912-9197)
- Elishama Kanu (ORCID: https://orcid.org/0000-0003-4959-9993)
- Tyler Jones
- Hamed Zaribafzadeh (ORCID: https://orcid.org/0000-0002-0363-395X)
- Bruce J. Rogers
- Ashley A. Fletcher (ORCID: https://orcid.org/0000-0003-2626-4867)
- JR Marks
- Kunling Tong
- Sara Raji
- Shannon J. McCall
- Daniel P. Nussbaum
- T. Clark Howell
Institutions
- Duke University (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1200/po-25-00115
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00